Nectin Therapeutics reports promising Phase 1 data for NTX1088

The clinical trial, designated KEYNOTE E92, enrolled 91 patients to test NTX1088 as both a monotherapy and alongside Merck’s Keytruda. The antibody targets CD155, a receptor known to suppress immune responses in the tumor microenvironment. Researchers observed no dose-limiting toxicities, leading to the selection of 1,750 mg as the recommended dosage for future expansion phases.

Among 41 evaluable patients receiving active dose levels, the combination therapy triggered partial responses in various cancer types, including gastric, bladder, melanoma, and non-small cell lung cancer. Many participants had previously undergone a median of four lines of therapy, including prior immune checkpoint inhibitors, underscoring the potential for NTX1088 in difficult-to-treat settings. Dr. Sarina A. Piha-Paul of MD Anderson Cancer Center, the study's lead investigator, noted the therapy’s tolerability and efficacy, supporting the transition toward Phase 2 trials involving less pretreated and biomarker-enriched patient cohorts.